Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study-Reference-Cited by-同舟云学术

Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study

Published:2020-01-03 Issue:2 Volume:86 Page:372-379
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Oh Jaeseong¹^ORCID,Huh Ki Young¹,Cho Young‐Gyu²,Cha Ji‐Eun³,Kim Se‐Jin³,Yoon Seo Hyun¹,Park Sung Sup⁴,Yoon Hyunyee⁵,Lee Jieon¹,Lee Howard¹⁶

Affiliation:

1. Department of Clinical Pharmacology and TherapeuticsSeoul National University College of Medicine and Hospital Seoul Republic of Korea

2. Y Biologics Daejeon Republic of Korea

3. HANDOK Inc. Seoul Republic of Korea

4. Department of Laboratory MedicineSeoul National University College of Medicine and Hospital Seoul Republic of Korea

5. Protein Immunology Core Facility, Biomedical Research InstitutesSeoul National University Hospital Seoul Republic of Korea

6. Department of Transdisciplinary Studies, Graduate School of Convergence Science and TechnologySeoul National University Seoul Republic of Korea

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14161

Reference29 articles.

1. Biologic basis for interleukin-1 in disease

2. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

3. Interleukin‐1, inflammasomes, autoinflammation and the skin;Contassot E;Swiss Med Wkly,2012

4. The IL-1 family: regulators of immunity

5. Interleukin-1 (IL-1) Pathway

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment;Life Sciences;2023-12

2. Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas;Heliyon;2023-04

3. Inflammasome activation: from molecular mechanisms to autoinflammation;Clinical & Translational Immunology;2022-01

4. Interleukin-1 Receptor Antagonist: A Promising Cytosine In Human Squamous Epithelial Cell Carcinoma;SSRN Electronic Journal;2022

5. In Translation: FcRn across the Therapeutic Spectrum;International Journal of Molecular Sciences;2021-03-17